CytoSorbents Announces a $6.25 Million Common Stock Financing Priced at-the-Market Under Nasdaq Rules, Along with a Concurrent Restructuring of Its Avenue Capital Credit Facility

CytoSorbents Corporation a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced a $6.25 million common stock financing.

CytoSorb
Registered Direct Offering

The Company has entered into securities purchase agreements with certain institutional and accredited investors and certain insiders of the Company for the issuance and sale in a registered direct offering (the "Offering") priced at-the-market under Nasdaq rules of (i) an aggregate of 556,681 shares (the "Common Shares") of the Company's common stock, par value $0.001 per share (the "Common Stock"), at a purchase price of $4.94 per share, and 96,527 shares of Common Stock to the Company's directors and certain executive officers at an offering price of $5.18 per share, which was the consolidated closing bid price of our Common Stock on The Nasdaq Capital Market on November 18, 2026, and (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 151,822 shares of Common Stock (the "Pre-Funded Warrant Shares," together with the Common Shares, the "Shares"), at a purchase price of $4.939 per Pre-Funded Warrant, equal to the purchase price per Common Share less $0.001. Each Pre-Funded Warrant is immediately exercisable for one share of Common Stock at an exercise price of $0.001 per Pre-Funded Warrant Share until such Pre-Funded Warrants are exercised in full.

The Offering is expected to consist of approximately $4.0 million of gross cash proceeds, with approximately 75% of the Offering subscribed for by existing shareholders and members of the Company's management and Board of Directors.

H.C. Wainwright & Co. is acting as exclusive placement agent for the Offering.  WBB Securities, LLC is acting as financial advisor in connection with the Offering.

The Offering is expected to close on or about November 20, 2026, subject to satisfaction of customary closing conditions. Gross proceeds from the Offering are expected to be approximately $4.0 million, before deducting placement agent fees, financial advisor fees and offering expenses payable by the Company. The Company intends to use the net proceeds for (i) the repayment of $3.0 million of outstanding principal under its existing loan agreement with Avenue Capital Group ("Avenue"), together with a $52,500 prepayment fee and a $270,000 final payment, and (ii) general corporate and working capital purposes.

Avenue Credit Facility Amendment

Concurrently with the Offering, the Company entered into the Third Amendment to Loan Documents (the "Avenue Amendment"), dated November 19, 2026, to its existing Loan and Security Agreement dated June 28, 2024, as amended, with Avenue. 

Key terms include:
  • Debt reduction of $5.25 million:  Repayment of $3.0 million of principal in cash from the Offering proceeds, plus a $52,500 prepayment fee and a $270,000 final payment, and satisfaction of $2.25 million of principal through the issuance of 455,465 shares of Common Stock to Avenue Venture Opportunities Fund, L.P. at the Offering price of $4.94 per share. Following these transactions, $12.25 million of principal will remain outstanding, down from $17.5 million. The Company expects to save approximately $0.7 million in interest expense over 12 months.
  • Maturity extended one year:  The maturity date is extended from July 1, 2027 to July 1, 2028.
  • Interest-only period extended 15 months:  Interest-only payments are extended through March 31, 2028, with a further three-month extension available if the Company has received FDA marketing approval for DrugSorb-ATR by that date, subject to other conditions.
  • New conversion rights:  Avenue's existing $2.0 million conversion right is replaced with the right to convert (i) up to $3.0 million of principal into Common Stock at $6.916 per share, equal to 140% of the $4.94 Offering price, exercisable at any time, and (ii) up to an additional $3.125 million of principal at $8.645 per share, equal to 175% of the Offering price, exercisable beginning on the earlier of FDA marketing approval of DrugSorb-ATR and January 1, 2028. Any conversion would further reduce the Company's outstanding debt.
    Other terms: The Avenue Amendment also modifies certain beneficial ownership limitations and financial covenants, provides certain registration rights and provides for a back-end fee of $250,000, payable on July 1, 2028 (or earlier repayment) and waived if Avenue achieves a net profit of at least 300% on the initial $2.25 million repayment shares.

Of the shares issued to Avenue in satisfaction of $2.25 million of principal, shares satisfying $1.0 million of principal (the "Registered Shares") will be issued pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-281062), and shares satisfying the remaining $1.25 million of principal will be issued in a transaction exempt from registration under the Securities Act of 1933, as amended (the "Securities Act"). The shares issued to Avenue are in addition to the securities issued in the Offering and will not generate additional cash proceeds to the Company. The cash repayment and issuance of shares to Avenue in satisfaction of the Company's indebtedness are expected to occur substantially concurrently with the closing of the Offering, subject to applicable closing conditions. 

About CytoSorbents Corporation:

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses includes, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

Contact the company, Cytosorbents Corp


Please login to view the submission form below, Or Register and get the login credentials in just two steps